

Talvey™ (talquetamab-tgvs) (Subcutaneous)

Document Number: EOCCO-0722

Last Review Date: 03/05/2024

Date of Origin: 09/05/2023

Dates Reviewed: 09/2023, 03/2024

I. Length of Authorization

Following initial inpatient administration of all step-up doses, coverage will be provided for 6 months and may be renewed.

II. Dosing Limits

A. Quantity Limit (max daily dose) [NDC Unit]:

- Talvey 3 mg/1.5 mL solution for injection in a single-dose vial: 3 vials per week
- Talvey 40 mg/mL solution for injection in a single-dose vial: 3 vials per week

B. Max Units (per dose and over time) [HCPCS Unit]:

- Step-up doses: 12 billable units (3 mg) on day one, 36 billable units (9 mg) on day four, and 160 billable units (40 mg) on day seven
- Maintenance: 160 billable units (40 mg) weekly thereafter

III. Initial Approval Criteria ¹

Coverage is provided in the following conditions:

- Patient is at least 18 years of age; **AND**
- Used as continuation therapy following inpatient administration of all step-up doses; **AND**
- Patient had an absence of unacceptable toxicity while on inpatient administration of step-up doses; **AND**

Universal Criteria ¹

- Prescribers are enrolled in the TECVAYLI and TALVEY REMS program; **AND**
- Patient does not have an active infection, including clinically important localized infections; **AND**
- Patient will be administered prophylaxis for infection according to local guidelines; **AND**
- Patient does not have active CNS involvement or clinical signs of meningeal involvement of multiple myeloma; **AND**

- Patient has not had an allogenic stem cell transplant within the previous six (6) months or an autologous stem cell transplant within the previous twelve (12) weeks; **AND**
- Patient weight and signs of oral and skin toxicity will be monitored at baseline and periodically during therapy; **AND**

Multiple Myeloma † ‡ Φ¹⁻⁵

- Used as a single agent; **AND**
- Patient has relapsed or refractory disease; **AND**
- Patient has received at least four (4) prior therapies, including a proteasome inhibitor (e.g., bortezomib, carfilzomib, ixazomib, etc.), an immunomodulatory agent (e.g., lenalidomide, thalidomide, pomalidomide, etc.), and an anti-CD38 monoclonal antibody (e.g., daratumumab, isatuximab, etc.)

† FDA Approved Indication(s); ‡ Compendia Recommended Indication(s); Φ Orphan Drug

IV. Renewal Criteria ¹

Coverage may be renewed based upon the following criteria:

- Patient continues to meet the indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; **AND**
- Disease response with treatment as defined by stabilization of disease or decrease in size of tumor or tumor spread; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: cytokine release syndrome (CRS), neurologic toxicity (e.g., Immune Effector Cell-Associated Neurotoxicity Syndrome [ICANS]), severe oral toxicity and weight loss, severe infections, severe cytopenias (e.g., neutropenia, thrombocytopenia, etc.), severe skin toxicity, hepatotoxicity, etc.

V. Dosage/Administration ¹

| Indication | Dose | | | |
|--------------------|---|----------------------|-------------------|------------|
| Multiple Myeloma | The recommended dosage is administered subcutaneously by a healthcare provider on a weekly or biweekly (every 2 weeks) dosing schedule, until disease progression or unacceptable toxicity. | | | |
| | Weekly Dosing schedule | Day | Dose ^a | |
| | Step-up dosing schedule | Day 1 | Step-up dose 1 | 0.01 mg/kg |
| | | Day 4 ^b | Step-up dose 2 | 0.06 mg/kg |
| Day 7 ^c | | First treatment dose | 0.4 mg/kg | |

| | | | | |
|--|---|--|----------------------------|-------------------------|
| | Weekly dosing schedule | One week after first treatment dose and weekly thereafter | Subsequent treatment doses | 0.4 mg/kg once weekly |
| <p>^a Based on actual body weight. ^b Dose may be administered between 2 to 4 days after the previous dose and may be given up to 7 days after the previous dose to allow for resolution of adverse reactions. ^c Maintain a minimum of 6 days between weekly doses.</p> | | | | |
| | Biweekly (every 2 weeks) Dosing schedule | Day | Dose ^a | |
| | Step-up dosing schedule | Day 1 | Step-up dose 1 | 0.01 mg/kg |
| | | Day 4 ^b | Step-up dose 2 | 0.06 mg/kg |
| | | Day 7 ^b | Step-up dose 3 | 0.4 mg/kg |
| | | Day 10 ^c | First treatment dose | 0.8 mg/kg |
| | Biweekly (every 2 weeks) dosing schedule | Two weeks after first treatment dose and 2 weeks thereafter ^d | Subsequent treatment doses | 0.8 mg/kg every 2 weeks |
| <p>^a Based on actual body weight. ^b Dose may be administered between 2 to 4 days after the previous dose and may be given up to 7 days after the previous dose to allow for resolution of adverse reactions. ^c Dose may be administered between 2 to 7 days after step-up dose 3. ^d Maintain a minimum of 12 days between biweekly (every 2 weeks) doses.</p> | | | | |
| <p><i>Note: Administer Talvey subcutaneously according to the step-up dosing schedule noted above to reduce the incidence and severity of cytokine release syndrome (CRS). Due to the risk of CRS and neurologic toxicity, including ICANS, patients should be hospitalized for 48 hours after administration of all doses within the Talvey step-up dosing schedule.</i></p> | | | | |

VI. Billing Code/Availability Information

HCPCS Code(s):

- J3055 – Injection, talquetamab-tgvs, 0.25 mg; 1 billable unit = 0.25 mg (*Effective 04/01/2024*)
- J9999 – Not otherwise classified, antineoplastic drugs (*Discontinue use on 04/01/2024*)
- C9163 – Injection, talquetamab-tgvs, 0.25 mg; 1 billable unit = 0.25mg (*Discontinue use on 04/01/2024*)

NDC(s):

- Talvey 3 mg/1.5 mL solution for injection in a single-dose vial: 57894-0469-xx
- Talvey 40 mg/mL solution for injection in a single-dose vial: 57894-0470-xx

VII. References

1. Talvey [package insert]. Horsham, PA; Janssen Biotech, Inc.; August 2023. Accessed January 2024.
2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for talquetamab. National Comprehensive Cancer Network, 2024. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed January 2024.
3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma, Version 2.2024. National Comprehensive Cancer Network, 2024. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed January 2024.
4. BGM Durie, J-L Harousseau, J S Miguel, et al on behalf of the International Myeloma Working Group. International uniform response criteria for multiple myeloma. *Leukemia*. Sep; 20(9):1467-73.
5. Schinke CD, Touzeau C, Minnema MC, et al. Pivotal phase 2 MonumentAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM). *Journal of Clinical Oncology* 2023 41:16_suppl, 8036-8036.

Appendix 1 – Covered Diagnosis Codes

| ICD-10 | ICD-10 Description |
|--------|--|
| C90.00 | Multiple myeloma not having achieved remission |
| C90.02 | Multiple myeloma in relapse |
| C90.10 | Plasma cell leukemia not having achieved remission |
| C90.12 | Plasma cell leukemia in relapse |
| C90.20 | Extramedullary plasmacytoma not having achieved remission |
| C90.22 | Extramedullary plasmacytoma in relapse |
| C90.30 | Solitary plasmacytoma not having achieved remission |
| C90.32 | Solitary plasmacytoma in relapse |
| Z85.79 | Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues |

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

The preceding information is intended for non-Medicare coverage determinations. Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologics. In addition, National Coverage Determinations (NCDs) and/or Local Coverage

Determinations (LCDs) may exist and compliance with these policies is required where applicable. Local Coverage Articles (LCAs) may also exist for claims payment purposes or to clarify benefit eligibility under Part B for drugs which may be self-administered. The following link may be used to search for NCD, LCD, or LCA documents: <https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications, including any preceding information, may be applied at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

| Medicare Part B Administrative Contractor (MAC) Jurisdictions | | |
|---|---|---|
| Jurisdiction | Applicable State/US Territory | Contractor |
| E (1) | CA, HI, NV, AS, GU, CNMI | Noridian Healthcare Solutions, LLC |
| F (2 & 3) | AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ | Noridian Healthcare Solutions, LLC |
| 5 | KS, NE, IA, MO | Wisconsin Physicians Service Insurance Corp (WPS) |
| 6 | MN, WI, IL | National Government Services, Inc. (NGS) |
| H (4 & 7) | LA, AR, MS, TX, OK, CO, NM | Novitas Solutions, Inc. |
| 8 | MI, IN | Wisconsin Physicians Service Insurance Corp (WPS) |
| N (9) | FL, PR, VI | First Coast Service Options, Inc. |
| J (10) | TN, GA, AL | Palmetto GBA, LLC |
| M (11) | NC, SC, WV, VA (excluding below) | Palmetto GBA, LLC |
| L (12) | DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA) | Novitas Solutions, Inc. |
| K (13 & 14) | NY, CT, MA, RI, VT, ME, NH | National Government Services, Inc. (NGS) |
| 15 | KY, OH | CGS Administrators, LLC |